



#6 DB
4/25/01 1651

RECEIVED

ATTORNEY'S DOCKET NO: H0535/7012/ERG/MAT

APR 16 2001


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant: Howard Green
Serial No: 09/620,783
Filed: July 21, 2000
For: LINKAGE OF AGENTS USING MICROPARTICLES
Examiner: Not yet assigned
Art Unit: 1651

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231 on the 4th day of April, 2001.


Maryanne Trevisan

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL

Sir:


Transmitted herewith are the following documents:

- ☒ Information Disclosure Statement/1449/references and applications cited
- ☒ Return Receipt Postcard


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No fee is required. If any fee is determined to be due by the Examiner, the Examiner is authorized to charged the appropriate fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,


Edward R. Gates, Reg. No. 31,616
Wolf, Greenfield & Sacks, P.C.
Federal Reserve Plaza, 600 Atlantic Avenue
Boston, MA 02210-2211
(617)720-3500
Attorneys for Applicants

Attorney Docket No. H0535/7012
Date: April 10, 2001
xndd



ATTORNEY'S DOCKET NO: **H0535/7012/ERG/MAT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Howard Green, et al.
Serial No: 09/620,783
Filed: July 21, 2000
For: LINKAGE OF AGENTS USING MICROPARTICLES
Examiner: Not yet assigned
Art Unit: 1651

TECH CENTER 1600/2900

APR 16 2001

RECEIVED

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 10 day of April, 2001.

Maryanne Trevisan

Commissioner for Patents
Washington, D.C. 20231

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

This Information Disclosure Statement has been filed more than three months after the filing date of this application but prior to the mailing date of the first Office Action. No fee is required.

Other Information

The Applicant hereby makes the following additional information of record in the above-identified application:

Applicant brings to Examiner's attention the existence of related applications:

Docket No.	Serial No.	Filing Date	Status
H0535/7001	08/245,601	05/18/94	Issued 5,525,336
H0535/7005	08/925,900	09/09/97	Pending
H0535/7007	09/234,358	01/20/99	Allowed
H0535/7009	09/359,920	07/22/99	Pending

Although these applications may not claim priority to one another, the inventor of this application is an inventor of one or more of the above-identified applications.

**EXPLANATION OF NON-ENGLISH LANGUAGE REFERENCES AND
REMARKS CONCERNING OTHER INFORMATION CITED**

The following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

French Patent Publications

EP 0285 474 "Skin Equivalent" was identified by the European Patent Examining Authority as an "X" reference with respect to claims 1 and 2 in PCT publication no. WO 94/18945. An English language translation of those portions which are relevant to the patentability of the claimed invention was submitted to the USPTO in the priority application Serial No. 09/359,920, filed July 22, 1999. Also submitted was Australian patent publication AU-A-13742 (in English) which corresponds to EP 0285 474.

EP 0511 116 "Antigens Recognized by Antibodies Found in Patient with Rheumatoid Arthritis, their Preparations and their Applications," was identified by the European Patent Examining Authority as an "X" reference with respect to PCT claims 26-30 in PCT publication no. WO 94/18945. Applicants bring to the Examiner's attention that these claims were directed to "modified corneocyte proteins or polypeptide fragments." An English language translation of those portions which are relevant to the patentability of the claimed invention was submitted to the USPTO in the priority application Serial No. 09/359,920, filed July 22, 1999.

Japanese Patent Publications

English language translations of portions of the Japanese patent applications are attached to the Japanese patent applications.

JP Application No. TOKU KAI HEI 5-56785 describes the nucleotide sequence of DNA encoding a human epidermis transglutaminase.

JP Application No. HEI 2-204407 describes hair cosmetic formulations containing transglutaminase extracted from guinea pig liver and hydrophilic polyalcohols.

JP Application No. HEI 3-38511 describes an ointment which contains transglutaminase that is obtained from the livers of animals.

JP Application No. SHOU 61-172807 describes cosmetic formulations containing proteins that have been crosslinked in solution by transglutaminase.

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

WOLF, GREENFIELD & SACKS, P.C.

By Edward R. Gates
Edward R. Gates, Reg. No. 31,616
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
Attorneys for Applicant(s)
Tel. no. (617) 720-3500

ATTORNEY'S DOCKET NO.: H0535/7012
DATE: April 12, 2001
XNDD